This page shows the latest Edurant news and features for those working in and with pharma, biotech and healthcare.
The combination of ViiV’s integrase inhibitor cabotegravir with non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine – a drug already sold by Janssen as Edurant – is just one of the two-drug
Along with dolutegravir/lamivudine for treatment-naïve patients, it has also been granted regulatory approval for Juluca, a combination of dolutegravir and Johnson &Johnson’s non-nucleoside RTI Edurant (rilpivirine) for
It combines ViiV’s own Tivicay (dolutegravir) the most widely prescribed integrase inhibitor worldwide, and J&J’s Edurant (rilpivirine).
The advisory committee issued a positive opinion for Juluca - which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) developed by Johnson &Johnson’s
Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant. The FDA has approved a dual therapy for HIV from GlaxoSmithKline’s ViiV joint venture with Johnson &Johnson, which ... The US regulator gave a green light to Juluca, which combines
inhibitor Edurant (rilpivirine) in the US and EU.
More from news
Approximately 2 fully matching, plus 14 partially matching documents found.
WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...